DSIP

Educational overview

Not FDA-approved; human evidence and safety information are very limited, with peptide impurity and immunogenicity concerns.

DSIP (delta sleep-inducing peptide, international nonproprietary name emideltide) is a nine-amino-acid peptide first isolated in 1977 from the cerebral venous blood of rabbits during electrically induced sleep by Schoenenberger, Monnier, and colleagues in Basel. It is classed as a putative endogenous sleep-modulating neuropeptide rather than a classical sedative. Its mechanism has never been settled; early reviews proposed modulation of adrenergic transmission and described effects on slow-wave (delta) sleep, hormone levels, pain perception, stress responses, and drug withdrawal in animals. DSIP-like immunoreactivity has been reported in human plasma and cerebrospinal fluid, but whether the measured material is the peptide itself or a related fragment remains unresolved.

The research base is almost entirely from the 1980s and early 1990s and was summarised in two reviews by Graf and Kastin in 1984 and 1986. Human data are sparse and small. A 1981 double-blind crossover study in six healthy volunteers reported increased sleep pressure after intravenous infusion, while a 1992 double-blind parallel-group study in sixteen chronic insomnia patients found only weak effects and concluded that short-term treatment was unlikely to offer major benefit. A separate crossover trial found no significant difference from placebo nights. Rapid degradation in plasma was documented in 1987. No adequately powered modern trial exists, and independent replication of the older findings has not been published.

DSIP is not approved by the FDA, the EMA, or other major regulators for any indication, in any route. In the United States it has been reviewed under the FDA compounding bulk drug substances programme, where the agency described emideltide as presenting an immunogenicity risk and lacking sufficient information to know whether it would cause harm. Products marketed online are typically labelled as research chemicals rather than medicines, and their purity, identity, and sterility are not independently verified. Injectable and intranasal formulations are both sold. In most jurisdictions DSIP is an unlicensed substance whose supply for human use falls outside any regulatory approval, and prescription status varies by country.

DSIP is generally supplied as a lyophilised powder without a regulator-reviewed product label, so storage guidance comes from the supplier rather than an approved monograph. Published work shows the peptide degrades and aggregates in biological fluids, and peptides in general are sensitive to heat, light, repeated freeze-thaw cycles, and prolonged storage after reconstitution. The beyond-use time of a reconstituted vial is not established for any DSIP product. For someone keeping records, a dose log that captures the supplier, lot number, reconstitution date, diluent, route, and storage temperature, alongside an inventory record of vials on hand, provides the traceability that a labelled pharmaceutical would otherwise supply.

Category

Investigational sleep peptide

Routes represented

Intranasal / Subcutaneous (SubQ)

Storage context

Follow the dispensed product or pharmacy label; storage and beyond-use time vary by formulation.